Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-25 @ 9:55 PM
Study NCT ID:
NCT04344158
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-20
First Post:
2020-04-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-11
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2020-04-10
First Submit QC Date:
None
Study First Post Date:
2020-04-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-18
Last Update Post Date:
2025-02-20
Last Update Post Date Type:
ACTUAL